ABIVAX Société Anonyme (EPA:ABVX)
France · Delayed Price · Currency is EUR 104.10
-1.40 (-1.33%)
May 11, 2026, 5:35 PM CET
ABIVAX Société Anonyme Revenue
In the year 2025, ABIVAX Société Anonyme had annual revenue of 4.57M EUR, down -63.29%. ABIVAX Société Anonyme had revenue of 440.00K in the quarter ending December 31, 2025, a decrease of -89.79%.
Revenue
4.57M
Revenue Growth
-63.29%
P/S Ratio
1,828.02
Revenue / Employee
66.23K
Employees
69
Market Cap
8.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.57M | -7.88M | -63.29% |
| Dec 31, 2024 | 12.45M | 7.83M | 169.40% |
| Dec 31, 2023 | 4.62M | 38.00K | 0.83% |
| Dec 31, 2022 | 4.58M | -7.38M | -61.68% |
| Dec 31, 2021 | 11.96M | 11.90M | 18,885.71% |
| Dec 31, 2020 | 63.00K | 40.00K | 173.91% |
| Dec 31, 2019 | 23.00K | 5.00K | 27.78% |
| Dec 31, 2018 | 18.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 174.66M |
| Cellectis | 67.79M |
| Genfit | 65.43M |
| Nanobiotix | 32.59M |
| MedinCell | 32.44M |
| Transgene | 7.21M |
| Inventiva | 6.76M |
| Sensorion | 5.81M |
ABIVAX Société Anonyme News
- 6 days ago - Abivax Repurchases Royalty Certificates And Prices $45M ADS Offering To Strengthen Balance Sheet - Nasdaq
- 6 days ago - Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares - GlobeNewsWire
- 13 days ago - Abivax call volume above normal and directionally bullish - TheFly
- 18 days ago - Abivax to Present Data on Obefazimod at Digestive Disease Week® - GlobeNewsWire
- 20 days ago - Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents - GlobeNewsWire
- 4 weeks ago - Abivax price target raised to EUR 120 from EUR 88 at Oddo BHF - TheFly
- 4 weeks ago - This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy? - The Motley Fool
- 5 weeks ago - Abivax appoints Michael Nesrallah as chief commercial officer - TheFly